ClinicalTrials.gg
RecruitingNCT06038461Updated Jul 24, 2026

An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of Advanced Neuroendocrine Tumors

A Phase 1/2 interventional study of Surufatinib Combined With Temozolomide and S-1 in Neuroendocrine Tumors, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-24.

Sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies testing temozolomide in Neuroendocrine Tumors — 3 open to participants now, 3 under way, none of them phase 3. Temozolomide · Neuroendocrine Tumors.

Planned enrollment
6th of 10
40 · median 41
Started
2023
the only one that year
Phase 1/2
Only one
of the 10
Registered
10th of 10
by date
Lead sponsor
1 of 10
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Among the 10 studies testing temozolomide in Neuroendocrine Tumors, this one is the 6th largest by planned enrollment, is the only one that started in 2023, is the only one in phase 1/2, and was the 10th registered.

Neuroendocrine Tumors

544 studies on the registry are indexed under Neuroendocrine Tumors; 136 are open to participants now.

Browse Neuroendocrine Tumors studies →

Open to participants now

3 of the 10 studies testing temozolomide in Neuroendocrine Tumors are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About temozolomide

Temozolomide: first FDA approval 1999 (TEMODAR), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 111 Neuroendocrine Tumors studies recruiting now, 72 (65%) set no upper age limit and 17 (15%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing temozolomide in Neuroendocrine Tumors, or all of them as a file.
02

Study summary

This is a prospective, open, single-center study evaluating the efficacy and safety of surufatinib Combined With Temozolomide and S-1 as the first-line treatment of advanced neuroendocrine tumors

03

Conditions studied

  • Neuroendocrine Tumors

Browse trials for

Keywords

  • Surufatinib
  • Temozolomide and S-1
  • First-line treatment
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18-75years (inclusive);
  • Histopathologically confirmed diagnosis of advanced MGMT0/1+ (G1, G2 or G3) neuroendocrine tumor (locally advanced, unresectable or distant );
  • Previously untreated with systemic therapy;
  • Have at least one according to v1.1;
  • performance status: 0-2(determined by investigator);
  • Expected survival time > 3 months;
  • Adequate hepatic, renal, heart, and hematologic functions;
  • Urine protein \< ++ . If Urine protein ≥ ++ ,the amount of urine protein in 24 hours ≤1.0g;
  • Before the first dose, serum HCG examination of potential childbearing-women must be negative; Men/Women of must agree to use a highly effective method (such as double barrier contraceptive method, condom, oral or injectable contraceptives and intrauterine device) throughout treatment and for at least 90 days after study completion.

Exclusion criteria

Exclusion Criteria:

  • Neuroendocrine cancer, adenocarcinoid, goblet cell carcinoid,
  • Functional NETs which need to control symptoms by long-acting somatostatin analogues;
  • Received a major surgery which requires at least 3 weeks after recovery time, to undergo surgery on treatment of this research within 4 weeks prior to treatment;
  • Have uncontrolled hypertension, defined as systolic blood pressure >140 mmHg or diastolic blood pressure >90 mm Hg, while under anti-hypertension treatment;
  • Patients with active ulcer, intestinal perforation and intestinal obstruction;
  • With active bleeding or bleeding tendency;
  • Severe history of cardiovascular and cerebrovascular diseases;
  • Other diagnosed within the previous 5 years, except basal cell carcinoma or cervical carcinoma in situ after radical resection.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Surufatinib Combined With Temozolomide and S-1

    Patients will receive surufatinib combined with temozolomide and S-1 once every three weeks as the second-line treatment until disease progression or intolerable toxicity or patients withdrawal of consent. Phase I: DLTs of surufatinib combined with temozolomide and S-1 will be evaluated based on NCI CTCAE v 5.0 in the first cycle.

    Drug: Surufatinib Combined With Temozolomide and S-1

Interventions

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR)

    the proportion of patients with complete response or partial response, using RESIST v1.1

    Time frame: approximately 1 years

Secondary outcomes

  1. Progression-Free Survival (PFS)

    time from first-dose to the first documented disease progression or death

    Time frame: approximately 1 years

  2. Disease Control Rate (DCR)

    the proportion of patients with complete response, partial response or stable disease, using RESIST v1.1

    Time frame: approximately 1 years

07

Study locations

1 of 1 sites recruiting
  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    Beijing, Beijing Municipality 100021, China
    Recruiting
    • Yihebali Chi, doctor · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Sep 2027, 48 months after the start.

Of 29 phase 1/2 interventional studies under Neuroendocrine Tumors, half reached primary completion within 84 months of starting (the median), counting those still running; a quarter within 52 and three quarters within 122. This study's planned 48 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2023
First posted
Sep 14, 2023
StartActual
Sep 15, 2023
Primary completionEst.
Sep 15, 2027
CompletionEst.
Sep 15, 2028
Last update
Jul 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06038461
Responsible party
Yihebali Chi, MD (Professor, Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences) — Principal investigator
First posted
Sep 14, 2023
Start date
Sep 15, 2023
Primary completion
Sep 15, 2027 (estimated)
Completion
Sep 15, 2028 (estimated)
Last update
Jul 24, 2026

Study contacts

Yihebali Chi, PhD
Contact
yihebalichi@hotmail.com
010-67781331

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Surufatinib · Temozolomide · Tegafur · Gimeracil · Oxonic Acid

Start the discussion